推进真菌角膜炎治疗:从传统的安福特素B疗法过渡到基于纳米载体的输送系统
Gourav Kumar1, Aians H Kalita1, Jabin Ahmed1
1Department of Pharmaceutics, ISF College of Pharmacy, Moga, 142001, Punjab, India.
Naunyn-Schmiedeberg's archives of pharmacology
|May 17, 2025
概括
性角膜炎 (FK) 治疗面临着传统药物的挑战. 纳米载体输送系统提供了一种有前途的解决方案,以改善对眼部感染的安福特素B (Am-B) 治疗.
科学领域:
- 眼科医生 眼科 眼科
- 菌类学 菌类学是指菌类学.
- 纳米技术 纳米技术
背景情况:
- 性角膜炎 (FK) 是一种严重的眼睛感染,导致视力丧失和潜在的核分裂.
- 目前的局部抗真菌药物有局限性,由于配方不佳,安福特 B (Am-B) 是最后的手段.
- 在注射Am-B用于眼科疾病的非标签性使用遭受不稳定性和不良保留.
研究的目的:
- 审查常规安福特瑞辛B (Am-B) 治疗真菌角膜炎 (FK) 的局限性.
- 突出基于纳米载体的传递系统在管理FK的潜力.
- 探索用于眼部药物输送的纳米载体策略的进展.
主要方法:
- 审查现有的关于真菌角膜炎治疗的文献.
- 分析与安福特里辛B (Am-B) 相关的药物技术挑战.
- 在眼部感染中探索各种纳米载体策略用于药物输送.
主要成果:
- 传统的Am-B眼科制剂因溶解性,稳定性和透性差而受到限制.
- 纳米载体系统显示出克服Am-B传递这些局限性的潜力.
- 临床前和临床进展表明,基于纳米载体的FK管理具有前途.
结论:
- 先进的眼科药物输送系统对于改善FK治疗结果至关重要.
- 基于纳米载体的Am-B输送为FK治疗提供了一种变革性的方法.
- 纳米技术有可能通过更有效和患者友好的解决方案彻底改变FK管理.
关键词:
氨基氨酸B (Amphotericin B) 是一种氨基氨酸.角 Corneal 角膜潰瘍 角膜潰瘍菌的角质炎是一种真菌性角质炎.感染 感染 感染管理策略 管理策略纳米技术 纳米技术病理生理学 病理生理学结构性质 结构性质 结构性质更多相关视频
相关概念视频
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...


